Diphenyl-amine derivatives: uses, process of synthesis and pharmaceutical compositions
AssigneeFaes Farma, S.A.
InventorsRosa Rodes Solanes, Neftali Garcia Dominguez, Beatriz Lopez Ortega, Melchor Alvarez De Mon Soto, Antonio De La Hera Martinez, Ana Munoz Munoz, Francisco Ledo Gomez
Life of this patent
Estimating the term…
Abstract
The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, prodrug or solvate thereof, a method of synthesis of said compounds, pharmaceutical compositions comprising them and their use as a medicament for treating inflammatory diseases.
Claims15
A compound of formula (I), or a salt, prodrug or solvate thereof:
- wherein:
- Ph is phenyl;
- n is 2, 3 or 4;
- R1 is selected from the group consisting of hydrogen and C1-C6 alkyl;
- R2 is a radical of formula —[[CH(R3)]m—R4], wherein
- m is 1;
- R3, where appropriate, is selected from the group consisting of hydrogen, phenyl and C1-C6 alkyl;
- R4 is selected from the group consisting of an unsubstituted heteroaryl, a substituted heteroaryl and a substituted aryl radical,
- said substituents being selected from the group consisting of C1-C6 alkyl, C7-C11 arylalkyl, phenyl, 5- or 6-membered heteroaryl, F, Cl, Br, I, trifluoromethyl, cyano, —N(Ra)(Rb), —ORe, —SRd or —C(O)Re;
- wherein Ra, Rb, Rc, Rd, and Re are independently selected from hydrogen, C1-C6 alkyl, phenyl and trifluoromethyl;
- or
- if R1 and/or R3 are different from hydrogen, then R4 may also be unsubstituted phenyl;
- or
- R1 and R2, together with the nitrogen atom to which they are attached, form a substituted or unsubstituted heteroaryl group, wherein said substituents are as defined above with the proviso that:
- 2-[(4,4-diphenyl-but-3-enylamino)-methyl]-phenol,
- 3-[(4,4-diphenyl-but-3-enylamino)-methyl]-phenol,
- 5-[(4,4-diphenyl-but-3-enylamino)-methyl]-2-methoxy-phenol,
- 4-[(4,4-diphenyl-but-3-enylamino)-methyl]-2,6-difluoro-phenol,
- benzyl-(5,5-diphenyl-pent-4-enyl)-ethyl-amine,
- 6-Chloro-9-(4,4-diphenyl-but-3-enyl)-9H-purine,
- 9-(4,4-Diphenyl-but-3-enyl)-9H-purin-6-ylamine, and
- 5-(4,4-Diphenyl-but-3-enyl)-4,5,6,7-tetrahydro-isoxazolo[4,5-c]pyridin-3-ol
- are not included in formula (I).
A method for treating inflammatory disease, comprising administering to a patient in need of such treatment a therapeutically amount of a compound of formula (I), or a pharmaceutically acceptable salt, prodrug or solvate thereof:
- wherein:
- Ph is phenyl;
- n is 2, 3 or 4;
- R1 is selected from the group consisting of hydrogen and C1-C6 alkyl;
- R2 is a radical of formula —[[CH(R3)]m—R4], wherein
- m is an integer selected from the group consisting of 1, 0 or 2;
- each R3, where appropriate, is selected from the group consisting of hydrogen and C1-C6 alkyl;
- R4 is selected from the group consisting of an unsubstituted heteroaryl, a substituted heteroaryl, unsubstitued aryl and a substituted aryl radical,
- said substituents being selected from the group consisting of C1-C6 alkyl, C7-C11 arylalkyl, phenyl, 5- or 6-membered heteroaryl, F, Cl, Br, I, trifluoromethyl, cyano, —N(Ra)(Rb), —ORc, —SRd or —C(O)Re;
- wherein Ra, Rb, Rc, Rd, and Re are independently selected from hydrogen, C1-C6 alkyl, phenyl and trifluoromethyl;
- or
- R1 and R2, together with the nitrogen atom to which they are attached, form a substituted or unsubstituted heteroaryl group, wherein said substituents are as defined above.
Dependencies are inferred from the claim text.